- Report
- January 2023
- 154 Pages
From €2008EUR$2,100USD£1,721GBP
€2869EUR$3,000USD£2,458GBP
- Report
- January 2023
- 229 Pages
Middle East, Africa
From €2008EUR$2,100USD£1,721GBP
€2869EUR$3,000USD£2,458GBP
- Report
- January 2023
- 152 Pages
North America
From €2008EUR$2,100USD£1,721GBP
€2869EUR$3,000USD£2,458GBP
- Report
- January 2023
- 151 Pages
Europe
From €2008EUR$2,100USD£1,721GBP
€2869EUR$3,000USD£2,458GBP
- Report
- January 2023
- 183 Pages
Asia Pacific
From €2008EUR$2,100USD£1,721GBP
€2869EUR$3,000USD£2,458GBP
- Report
- November 2022
- 291 Pages
Global
From €3046EUR$3,185USD£2,610GBP
€4351EUR$4,550USD£3,728GBP
- Report
- August 2023
- 77 Pages
Global
From €3500EUR$3,921USD£3,104GBP
- Report
- March 2024
- 50 Pages
Global
From €2534EUR$2,650USD£2,171GBP
- Report
- March 2024
- 50 Pages
Global
From €2534EUR$2,650USD£2,171GBP
Primaquine is an antimalarial drug used to treat and prevent malaria caused by Plasmodium vivax and Plasmodium ovale. It is also used to treat infections caused by other protozoal parasites, such as Babesia microti and Toxoplasma gondii. Primaquine is a member of the 8-aminoquinoline class of drugs, which are known for their ability to inhibit the growth of malaria parasites. Primaquine is available in both oral and intravenous formulations, and is typically used in combination with other antimalarial drugs.
The Primaquine market is a rapidly growing segment of the Infectious Diseases Drugs market. Primaquine is increasingly being used to treat and prevent malaria in both endemic and non-endemic regions. The drug is also being used to treat other protozoal infections, such as Babesia microti and Toxoplasma gondii.
Companies in the Primaquine market include GlaxoSmithKline, Sanofi, Novartis, Pfizer, Merck, and Bayer. Show Less Read more